EGFR and non-small cell lung carcinoma: As previously discussed, patients with EGFR ex20ins mutations -positive NSCLC face significant barriers to receiving treatment, with minimal benefits from EGFR TKIs, chemotherapy, and immunotherapy, resulting in poor survival outcomes.